Novel Nucleic Acid Sequencing Technology Development - Direct to Phase II (R44)

The summary for the Novel Nucleic Acid Sequencing Technology Development - Direct to Phase II (R44) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Novel Nucleic Acid Sequencing Technology Development - Direct to Phase II (R44): This Funding Opportunity Announcement (FOA) solicits Direct to Phase II R44 SBIR grant applications from small businesses to develop novel technologies that will enable new approaches to DNA and direct RNA sequencing. Applicants may propose to develop novel complete sequencing systems, investigate challenges underlying key novel system components, or propose improvements of at least an order of magnitude improvement to existing systems. Exploration of methods other than those currently in use is highly encouraged. High-risk/high-payoff applications are appropriate to achieve the goals of this FOA.

Federal Grant Title:	Novel Nucleic Acid Sequencing Technology Development - Direct to Phase II (R44)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-HG-15-039
Type of Funding:	Grant
CFDA Numbers:	93.172
CFDA Descriptions:	Human Genome Research
Current Application Deadline:	Aug 7, 2016
Original Application Deadline:	Aug 7, 2016
Posted Date:	Oct 27, 2015
Creation Date:	Oct 27, 2015
Archive Date:	Sep 7, 2016
Total Program Funding:
Maximum Federal Grant Award:	none
Minimum Federal Grant Award:	none
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following:
Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-15-039.html
Grant Announcement Contact: NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants: • Genomic Variant Interactions With Other Variants Or The Environment (UM1 Clinical Trials N...; • Computational Modeling and Analysis of the Impact of Genomic Variation on Function (UM1, C...; • Systematic Characterization of Genomic Variation to Assess Effects of Individual Variants ...; • IGVF Data and Coordinating Center (U24 Clinical trials Not Allowed); • GREGoRi Innovation Projects (U01 Clinical Trial Optional); • Near-Term Technology Development for Genome Sequencing - SBIR (R43/R44); • Near-Term Technology Development for Genome Sequencing - STTR (R41/R42); • Revolutionary Genome Sequencing Technologies - The $1000 Genome - SBIR (R43/R44)
More Grants from the National Institutes of Health: • Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinic...; • Immune Tolerance Network (UM1 Clinical Trial Required); • Coordinating Center for National Resource Network for the Study of Human Auditory and Vest...; • National Resource Network for the Study of Human Auditory and Vestibular Disorders (U24 Cl...; • Pilot and Feasibility Studies in Preparation for Substance Use and HIV Prevention Interven...